Rubicon Research Q3 FY26 Triumph: ₹476 Cr Revenue, ₹72.8 Cr Profit Pharma Powerhouse Accelerates Growth

Earnings Breakdown
Rubicon Research Ltd, an India-based specialty pharmaceutical innovator targeting regulated markets like the US, unveiled impressive December quarter (Q3 FY26) figures on February 3, 2026. Consolidated revenue from operations hit ₹4.76 billion (₹476 crore), with net profit at ₹728 million (₹72.8 crore), fueled by oral solids, injectables, topicals, and drug-device tech like RubiERT.

This follows Q2 FY26's ₹412 crore revenue and ₹53.9 crore profit, signaling sustained momentum in exports (USD revenue up).

Key Highlights

• Top-Line Boom: Rev from ops ₹4.76 bln (₹476 Cr); broad-based growth across top products <60% share.
• ​Bottom-Line Surge: Consol net profit ₹728 mln (₹72.8 Cr); EBITDA margins ~23% expected sustained.
• R&D Focus: 10-11% of revenue invested; 93% commercialization rate; 2 new approvals Q2.
• ​Trajectory: H1 FY26 revenue trajectory robust; cash flow strong at ₹605 Mn Q2; debt manageable.

Sources: Marketscreener, Rubicon Investor Deck, Prysm, Scanx